ArticlePloS one2026
Treatment terminations during radiation therapy: A retrospective descriptive single-center analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy (RT) is a cornerstone of cancer management, substantially improving local tumor control and overall survival. However, a subset of patients fail to complete the prescribed RT course. Identifying the factors associated with treatment termination is essential to enhancing cancer care delivery and patient outcomes.
methodsThis retrospective, single-center analysis included 10039 patients who underwent RT between January 2020 and December 2024. Patients who terminated treatment before completion were identified in institutional RT records. Demographic and clinical characteristics, treatment intent, and reasons for termination were primarily evaluated using descriptive statistical analyses, with exploratory comparative analyses performed between curative- and palliative-intent groups.
resultsBetween 01/01/2020 and 12/31/2024, RT was terminated in 297/10039 patients (2.96%). The most leading causes of termination was deterioration in performance status (143 patients, 48.1%). Of these, 170 patients (57.2%) had been treated with palliative intent. Lung cancer (96 patients, 32.3%) was the most frequent primary diagnosis, while the brain (92 patients, 31%) was the most commonly irradiated site. The median number of prescribed fractions was 13 (range: 2-44), and patients completed a median of 51.6% (range: 5-93%) of these fractions before termination. The most common reason was deterioration in performance status (48.1%). Treatment termination rates were significantly higher in palliative cases compared with curative cases (6.13% [170/2,772] vs. 1.75% [127/7,267]; χ² = 134.4; p < 0.001). Relative risk analysis indicated that palliative-intent patients had a 3.50-fold higher risk of treatment termination. Performance deterioration was more frequent in the palliative group (72.4% vs. 27.3%; p < 0.001). Treatment-related toxicity (grade III-IV) occurred predominantly in curative-intent patients (88.9% vs. 11.1%; p < 0.001).
conclusionMost RT terminations occurred among patients with poor performance status and advanced disease. These findings suggest that multidisciplinary supportive care may be relevant and should be evaluated in future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.